Skip to Main Content Menu Button

Press Releases

Triplet Therapeutics Appoints Kathy Biberstein, J.D., and Stephen Webster to its Board of Directors

November 17, 2020

Triplet Therapeutics to Present at Stifel Virtual Healthcare Conference

November 16, 2020

Triplet Therapeutics Completes Enrollment of SHIELD HD Natural History Study of Huntington’s Disease

November 12, 2020

Triplet Therapeutics Announces Participation in Natural History Study of Myotonic Dystrophy Type 1

August 18, 2020

Triplet Therapeutics to Present at Upcoming Events

August 4, 2020

Triplet Therapeutics Appoints Alan Buckler, Ph.D., as Chief Scientific Officer

July 23, 2020

Triplet Therapeutics Selects Clinical Candidate for Novel Treatment of Repeat Expansion Disorders

July 21, 2020

In the News

Prospects for agents aimed at stopping neuronal loss brighten, driven by new mechanistic understanding

Nature Biotechnology
March 9, 2020

What unifies Huntington’s, spinocerebellar ataxia and myotonic dystrophy? Ness Bermingham’s new startup looks to drug that

Endpoints News
December 17, 2019

Cambridge startup targeting Huntington’s officially debuts after raising $59m

Boston Globe
December 17, 2019

Triplet Therapeutics launches with $59 million to develop antisense therapies for Huntington’s and more

Chemical and Engineering News
December 17, 2019

Atlas, MPM, Partners funnel $49M into a new gene-silencing startup

Boston Business Journal
December 17, 2019

Triplet Therapeutics Unveils $59M to Try Hairpin Fix for Huntington’s

Xconomy
December 17, 2019

Triplet debuts with $59M, therapies for repeat expansion disorders

BioCentury
December 17, 2019

Triplet Therapeutics launches with $59M, Nessan Bermingham at the wheel

FierceBiotech
December 17, 2019

Presentations

Targeting DNA Damage Response genes with oligonucleotides for therapeutic modulation of HTT somatic instability

Media contact

Mary Carmichael
Ten Bridge Communications
mary@tenbridgecommunications.com
617-413-3543

Stay Connected